Sevelamer decreases serum uric acid concentration through adsorption of uric acid in maintenance hemodialysis patients

Internal Medicine

Volumn 48, Issue 6, 2009, Pages 415-420

  Ohno, Iwao ^a   Yamaguchi, Yuichiro ^a   Saikawa, Hajime ^a   Uetake, Daijiro ^a   Hikita, Miho ^a   Okabe, Hideaki ^a   Ichida, Kimiyoshi ^b   Hosoya, Tatsuo ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

AST 120; Hemodialysis; Hyperphosphatemia; Hyperuricemia; Sevelamer

Indexed keywords

ALLOPURINOL; AST 120; CALCIUM; DIURETIC AGENT; FUROSEMIDE; PHOSPHATE BINDING AGENT; SEVELAMER; URIC ACID;

ADD ON THERAPY; ADSORPTION; ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYDROGEL; HYPERPHOSPHATEMIA; HYPERURICEMIA; IN VITRO STUDY; JAPAN; MAJOR CLINICAL STUDY; MALE; PHOSPHATE BLOOD LEVEL; PRESCRIPTION; TREATMENT DURATION; URIC ACID BLOOD LEVEL;

ABSORPTION; ADULT; AGED; AGED, 80 AND OVER; CHELATING AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERURICEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POLYAMINES; RENAL DIALYSIS; TIME FACTORS; TREATMENT OUTCOME; URIC ACID;

EID: 67650086604     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.48.1817     Document Type: Article

References (20)

1. Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality in chronic hemodialysis patients. J Am Soc Nephrol 12: 2131-2138, 2001.
2. Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31: 607-617, 1998.
3. Burke S, Slatopolsky E, Goldberg D. Renagel, a novel calcium-and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant 12: 1640-1644, 1997.
4. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245-252, 2002.
5. Drayer DE. Active drug metabolites and renal failure. Am J Med 62: 486-489, 1997.
6. Garg JP, Chasan-Taber S, Blair A, et al. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis. A randomized clinical trial. Arthritis Rheum 52: 290-295, 2005.
7. Nakai S, Masakane I, Akiba T, et al. An overview of dialysis treatment in Japan. J Jpn Soc Dial Ther 40: 1-30, 2007 (in Japanese).
8. Alderman MH, Cohen H, Madhavan S, et al. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 34: 144-150, 1999.
9. Franse LV, Pahor M, di Bari M, et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J hypertens 18: 1149-1154, 2000.
10. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 359: 995-1003, 2002.
11. Hoieggen A, Alderman MH, Kjeldsen SE, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 65: 1041-1049, 2004.
12. Siu YP, Leung KT, Tong MK, et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 47: 51-59, 2005.
13. Becker MA, Schumacher HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353: 2450-2461, 2005.
14. Yokoyama K, Katoh N, Kasai K, et al. The influences of method of calcium correction and the timing of blood collection on application of the K/ DOQI clinical practice guidelines for bone metabolism and disease in Japan. Ther Apher Dial 10: 257-261, 2006.
15. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349: 1207-1215, 2003.
16. Burke SK, Dillon MA, Hemken DE, et al. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients. Adv Ren Replace Ther 10: 133-145, 2003.
17. Aoyama I, Miyazaki T, Niwa T. Preventive effects of an oral sorbent on nephropathy in rats. Miner Electrolyte Metab 25: 365-372, 1999.
18. Akizawa T, Koide K, Koshikawa S. Effects of AST-120 on patients with chronic renal failure. Results of the nationwide clinical study. Kidney Dialysis 45: 373-388, 1998.
19. Sanaka T, Akizawa T, Koide K, et al. Protective effect of an oral adsorbent on renal function in chronic renal failure: Determinants of its efficacy in diabetic nephropathy. Ther Apher Dial 8: 232-240, 204.
20. Hatch M, Vaziri ND. Enhanced enteric excretion of urate in rats with chronic renal failure. Clin Sci 86: 511-516, 1994.